Trial · NCT07294469
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Unified Parkinson's Disease Rating Scale (UPDRS) I,II,III | Evaluations will be conducted at the time of randomization and will serve as baseline data. | The UPDRS is a clinical tool to assess the severity of Parkinson's disease. It consists of: Part I: Mentation, Behavior, and Mood (cognitive and psychiatric symptoms); Part II: Activities of Daily Living (self-reported motor activities); Part III: Motor Examination (clinician-assessed motor symptoms); The combined score of Parts I, II, and III reflects overall disease severity. |
| Primary | Unified Parkinson's Disease Rating Scale (UPDRS) I,II,III | Evaluations will be conducted at the fourth week after the start of the intervention. | The UPDRS is a clinical tool to assess the severity of Parkinson's disease. It consists of: Part I: Mentation, Behavior, and Mood (cognitive and psychiatric symptoms); Part II: Activities of Daily Living (self-reported motor activities); Part III: Motor Examination (clinician-assessed motor symptoms); The combined score of Parts I, II, and III reflects overall disease severity. |
| Primary | Unified Parkinson's Disease Rating Scale (UPDRS) I,II,III | Evaluations will be conducted at the fourth week after the end of the intervention, i.e. the eighth week after start of intervention. | The UPDRS is a clinical tool to assess the severity of Parkinson's disease. It consists of: Part I: Mentation, Behavior, and Mood (cognitive and psychiatric symptoms); Part II: Activities of Daily Living (self-reported motor activities); Part III: Motor Examination (clinician-assessed motor symptoms); The combined score of Parts I, II, and III reflects overall disease severity. |
| Primary | Pittsburgh Sleep Quality Index (PSQI) | Evaluations will be conducted at the time of randomization and will serve as baseline data. | The PSQI is a self-report questionnaire assessing sleep quality and disturbances over the past month. It consists of 19 items across 7 domains: sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. |
| Primary | Pittsburgh Sleep Quality Index (PSQI) | Evaluations will be conducted at the fourth week after the start of the intervention. | The PSQI is a self-report questionnaire assessing sleep quality and disturbances over the past month. It consists of 19 items across 7 domains: sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. |
| Primary | Pittsburgh Sleep Quality Index (PSQI) | Evaluations will be conducted at the fourth week after the end of the intervention, i.e. the eighth week after start of intervention. | The PSQI is a self-report questionnaire assessing sleep quality and disturbances over the past month. It consists of 19 items across 7 domains: sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. |
| Secondary | Parkinson's Disease Sleep Scale-2 (PDSS-2) | Evaluations will be conducted at the time of randomization and will serve as baseline data. | The PDSS-2 is a self-reported tool designed to assess sleep disturbances specifically in individuals with Parkinson's disease. It includes 15 items covering various sleep-related issues such as sleep onset, duration, nocturnal motor symptoms, and daytime sleepiness. |
| Secondary | Parkinson's Disease Sleep Scale-2 (PDSS-2) | Evaluations will be conducted at the fourth week after the start of the intervention. | The PDSS-2 is a self-reported tool designed to assess sleep disturbances specifically in individuals with Parkinson's disease. It includes 15 items covering various sleep-related issues such as sleep onset, duration, nocturnal motor symptoms, and daytime sleepiness. |
| Secondary | Parkinson's Disease Sleep Scale-2 (PDSS-2) | Evaluations will be conducted at the fourth week after the end of the intervention, i.e. the eighth week after start of intervention. | The PDSS-2 is a self-reported tool designed to assess sleep disturbances specifically in individuals with Parkinson's disease. It includes 15 items covering various sleep-related issues such as sleep onset, duration, nocturnal motor symptoms, and daytime sleepiness. |
| Secondary | Parkinson's Disease Questionnaire (PDQ-39) | Evaluations will be conducted at the time of randomization and will serve as baseline data. | The PDQ-39 is a 39-item self-report questionnaire designed to assess health-related quality of life in people with Parkinson's disease. It covers 8 domains: mobility, activities of daily living, emotional well-being, stigma, social support, cognitions, communication, and sleep. |
| Secondary | Parkinson's Disease Questionnaire (PDQ-39) | Evaluations will be conducted at the fourth week after the start of the intervention. | The PDQ-39 is a 39-item self-report questionnaire designed to assess health-related quality of life in people with Parkinson's disease. It covers 8 domains: mobility, activities of daily living, emotional well-being, stigma, social support, cognitions, communication, and sleep. |
| Secondary | Parkinson's Disease Questionnaire (PDQ-39) | Evaluations will be conducted at the fourth week after the end of the intervention, i.e. the eighth week after start of intervention. | The PDQ-39 is a 39-item self-report questionnaire designed to assess health-related quality of life in people with Parkinson's disease. It covers 8 domains: mobility, activities of daily living, emotional well-being, stigma, social support, cognitions, communication, and sleep. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07294469/registered